Broncus Holding Corporation
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for l… Read more
Broncus Holding Corporation (BRNHF) - Net Assets
Latest net assets as of June 2025: $160.38 Million USD
Based on the latest financial reports, Broncus Holding Corporation (BRNHF) has net assets worth $160.38 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($165.67 Million) and total liabilities ($5.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $160.38 Million |
| % of Total Assets | 96.81% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1.92 |
Broncus Holding Corporation - Net Assets Trend (2019–2024)
This chart illustrates how Broncus Holding Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Broncus Holding Corporation (2019–2024)
The table below shows the annual net assets of Broncus Holding Corporation from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $169.48 Million | -8.57% |
| 2023-12-31 | $185.37 Million | -13.08% |
| 2022-12-31 | $213.27 Million | -12.00% |
| 2021-12-31 | $242.35 Million | +297.93% |
| 2020-12-31 | $-122.44 Million | -65.73% |
| 2019-12-31 | $-73.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Broncus Holding Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35186900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.99K | 0.01% |
| Other Components | $646.04 Million | 381.19% |
| Total Equity | $169.48 Million | 100.00% |
Broncus Holding Corporation Competitors by Market Cap
The table below lists competitors of Broncus Holding Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ACHILLES THERAP.SP.ADS/1
F:698
|
$28.46 Million |
|
Ekso Bionics Holdings Inc
NASDAQ:EKSO
|
$28.47 Million |
|
JMC Electronics Co Ltd
TW:6552
|
$28.47 Million |
|
NicOx S.A.
PA:ALCOX
|
$28.49 Million |
|
Sono-Tek Corp
NASDAQ:SOTK
|
$28.44 Million |
|
Mahkota Group Tbk PT
JK:MGRO
|
$28.44 Million |
|
Saultech Technology Co., Ltd
TWO:6812
|
$28.43 Million |
|
Atlas Resources Tbk
JK:ARII
|
$28.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Broncus Holding Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 185,371,000 to 169,478,000, a change of -15,893,000 (-8.6%).
- Net loss of 15,303,000 reduced equity.
- Other comprehensive income decreased equity by 53,668,433.
- Other factors increased equity by 53,078,433.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-15.30 Million | -9.03% |
| Other Comprehensive Income | $-53.67 Million | -31.67% |
| Other Changes | $53.08 Million | +31.32% |
| Total Change | $- | -8.57% |
Book Value vs Market Value Analysis
This analysis compares Broncus Holding Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.23x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.14 | $0.08 | x |
| 2020-12-31 | $-0.23 | $0.08 | x |
| 2021-12-31 | $0.46 | $0.08 | x |
| 2022-12-31 | $0.44 | $0.08 | x |
| 2023-12-31 | $0.38 | $0.08 | x |
| 2024-12-31 | $0.35 | $0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Broncus Holding Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -188.21%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.04x
- Recent ROE (-9.03%) is above the historical average (-22.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -395.55% | 0.37x | 0.00x | $-24.87 Million |
| 2020 | 0.00% | -1480.12% | 0.08x | 0.00x | $-36.20 Million |
| 2021 | -96.97% | -2164.94% | 0.04x | 1.04x | $-259.24 Million |
| 2022 | -13.18% | -297.84% | 0.04x | 1.04x | $-49.43 Million |
| 2023 | -15.15% | -273.92% | 0.05x | 1.06x | $-46.63 Million |
| 2024 | -9.03% | -188.21% | 0.05x | 1.04x | $-32.25 Million |
Industry Comparison
This section compares Broncus Holding Corporation's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Broncus Holding Corporation (BRNHF) | $160.38 Million | 0.00% | 0.03x | $28.45 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |